我們已在上線! 進一步了解
RCEL圖示

Avita Medical

13.04 USD
-0.37
2.76%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
12.92
-0.12
0.92%
1天
-2.76%
5天
-2.1%
1個月
24.78%
3個月
161.85%
6個月
161.32%
今年迄今
275.79%
1年
142.38%
5年
-23.52%
10年
-65.09%
 

關於: Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

員工: 226

新聞

正面
中性
負面
市場情緒 3個月
正面 23.5%
中性 76.5%
負面 0%
中性
Seeking Alpha
5 天前
Leading Indicators For The October Breakout Cycle
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.
Leading Indicators For The October Breakout Cycle
中性
Seeking Alpha
上個月
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
中性
GlobeNewsWire
上個月
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer | New York Morgan Stanley 24th Annual Global Healthcare Conference – Wednesday, September 16, 2026 | 1:05 p.m.
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
正面
Zacks Investment Research
上個月
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
正面
Zacks Investment Research
上個月
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
正面
Seeking Alpha
上個月
AVITA Medical: Favorable Reimbursements For Skin Wound Care
AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive clinical economics also broaden RCEL's long-term potential. Management said they should reach their cash flow breakeven target by Q4 2026, which would further derisk the stock as a whole.
AVITA Medical: Favorable Reimbursements For Skin Wound Care
中性
MarketBeat
上個月
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft.
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
中性
Seeking Alpha
上個月
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
中性
GlobeNewsWire
2 個月前
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
正面
MarketBeat
2 個月前
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets.
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
價格圖表採用Lightweight Charts™實作